Study Design We propose a prospective observational study following the STROBE guidelines in which we will follow-up study subjects after cessation of NA for 48 weeks. HBsAg-positive patients from our clinic taking either entecavir or tenofovir therapy will be tested for HBsAg levels and screened for study eligibility. Those with serum HBsAg levels <200 IU/mL and fulfilling the inclusion and exclusion criteria listed above will be seen by one of the study investigators, who would explain the study objectives and offer the option of treatment discontinuation.